Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9151226 | 0.86 | KMT2A (0.50) | MAPK1CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL9147815 | 0.81 | KMT2A (0.48) | KMT2AMAPK9ALDH1A1POLBPTGS1 | |
| SCHEMBL7606367 | 0.79 | ALDH1A1 (0.57) | MAPK1CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL9146883 | 0.79 | TAS1R3 (0.49) | KMT2AMAPK9ALDH1A1LMNANPC1 | |
| SCHEMBL6232744 | 0.77 | KMT2A (0.53) | MAPK1CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL9145475 | 0.77 | KMT2A (0.50) | MAPK1CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL5858099 | 0.76 | KMT2A (0.62) | MAPK1CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL6367100 | 0.75 | MAPK9 (0.68) | MAPK1CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL6367096 | 0.75 | MAPK9 (0.68) | MAPK1CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL3728878 | 0.74 | KMT2A (0.59) | MAPK1CYP1A2CYP3A4CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1282397-B1 | USE OF COMPOUNDS CONTAINING A THIO-ETHER, SULPHOXIDE OR SULPHONE FUNCTION AS COSMETIC ANTI-POLLUTION AGENT | OREAL (FR) | 2005-05-04 | — | — | EP | claimed |
| US-20040037856-A1 | Use of compounds containing a thio-ether, sulphoxide or sulphone function as cosmetic anti-pollution agent | L'OREAL (FR) | 2004-02-26 | — | — | US | claimed |
| EP-0858319-B1 | USE OF CARBOXYLIC ACIDS HAVING A SULPHUR FUNCTION FOR PROMOTING SKIN EXFOLIATION OR STIMULATING EPIDERMAL REGENERATION | OREAL (FR) | 2003-07-23 | — | — | EP | claimed |
| US-6153649-A | Use of carboxylic acids having a sulphur function for promoting skin exfoliation or stimulating epidermal regeneration | L'OREAL (FR) | 2000-11-28 | — | — | US | claimed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090111737-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2009-04-30 | — | — | US | disclosed |
| US-20090111737-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2009-04-30 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-10-30 | — | — | US | disclosed |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-10-30 | — | — | US | disclosed |
| US-7211695-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211695-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-7179794-B2 | Multivalent macrolide antibiotics | THERAVANCE, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179794-B2 | Multivalent macrolide antibiotics | THERAVANCE, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7173039-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173039-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20040037856-A1 | Use of compounds containing a thio-ether, sulphoxide or sulphone function as cosmetic anti-pollution agent | L'OREAL (FR) | 2004-02-26 | — | — | US | disclosed |
| US-6153649-A | Use of carboxylic acids having a sulphur function for promoting skin exfoliation or stimulating epidermal regeneration | L'OREAL (FR) | 2000-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040037856-A1 | Use of compounds containing a thio-ether, sulphoxide or sulphone function as cosmetic anti-pollution agent | TST, STS, MPST | MAPK1 3914/4885CYP1A2 1496/4885CYP3A4 1501/4885 |
| US-20090306134-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | MAPK1 3288/4885CYP1A2 2058/4885CYP3A4 2099/4885 |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | ADRB2, ADRB1, ADRA2B | MAPK1 3338/4885CYP1A2 601/4885CYP3A4 1760/4885 |
| US-20090111737-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | MAPK1 4374/4885CYP1A2 2966/4885CYP3A4 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.